Sensitive Nanozyme Test May Provide Rapid Point-of-Care Diagnosis of Ebola
|
By LabMedica International staff writers Posted on 24 Sep 2015 |

Image: In the new nanozyme immunochromatographic strip test for Ebolavirus (EBOV), the magnetic (A) and catalytic (B) properties of the nanozymes (Fe3O4 magnetic nanoparticles (MNPs)) make the signal 100 times stronger than standard strips with colloidal-gold nanoparticles, generating a deeper color reaction that can be more clearly seen by the naked eye (Image courtesy of Duan D et al., 2015, and Elsevier).
Researchers have developed a simple low-cost Ebolavirus (EBOV) test based on detection technology using magnetic nanoparticles that has shown 100x higher sensitivity than the standard immunochromatographic ELISA gold strip test.
In a new study led by Xiyun Yan, professor at the Institute of Biophysics, Chinese Academy of Sciences (Beijing, China), a nanozyme strip test was developed that is similar to the gold strip test but instead uses Fe3O4 magnetic nanoparticles (nanozymes) that enhance the signal via their intrinsic enzyme-like activity. Results showed 100x higher sensitivity than the gold strip test—the new test detects EBOV glycoprotein at concentrations as low as 1 nanogram/mL. Also, to concentrate the virus particles in the sample, the tube bottom is simply held against a magnet, so no expensive lab equipment is needed.
Early accurate detection is a key to controlling the Ebola outbreak as patients can then be isolated and treated. Current tests are either too expensive to be useful where they are most needed, or not sensitive enough to provide accurate diagnosis. PCR testing is highly sensitive but expensive and complicated, requiring specialized skills and equipment. Testing with the ELISA gold strip is inexpensive, but sensitivity is low.
“Our new strip test is a simple, one-step test that is cheap and easy to use, and provides a visible signal, which means people don’t need training to use it. We think it will be especially helpful in rural areas,” said Prof. Yan, “We’re very excited about our new nanozyme test, as it is much more sensitive and you don’t need any specialist equipment to get a quick, accurate result.” Her colleagues at the Chinese Center for Disease Control and Prevention (CDC) will field-test it in West Africa for its EBOV diagnostic and screening potential. The researchers are also developing automatic equipment to reduce risk of test contamination from hand-contact.
The nanozyme test is the result of an interdisciplinary collaboration of scientists and clinicians. The researchers are collaborating to develop this robust technology further as it can be applied for detection of other biological molecules, making it useful to diagnose additional infectious diseases and to potentially detect cancer tumors. It is also being tested for its potential to help in decontamination for wastewater treatment.
“We had an idea and talked to many people about it, and the result is a test that will overcome a problem,” said Prof. Yan, “We have built strong collaborations that have finally made this method successful, and we’re looking forward to applying it to many other areas.”
The study, by Duan D et al., was published online ahead of print 11 May 2015, in the journal Biosensors and Bioelectronics.
Related Links:
Chinese Academy of Sciences
Elsevier
In a new study led by Xiyun Yan, professor at the Institute of Biophysics, Chinese Academy of Sciences (Beijing, China), a nanozyme strip test was developed that is similar to the gold strip test but instead uses Fe3O4 magnetic nanoparticles (nanozymes) that enhance the signal via their intrinsic enzyme-like activity. Results showed 100x higher sensitivity than the gold strip test—the new test detects EBOV glycoprotein at concentrations as low as 1 nanogram/mL. Also, to concentrate the virus particles in the sample, the tube bottom is simply held against a magnet, so no expensive lab equipment is needed.
Early accurate detection is a key to controlling the Ebola outbreak as patients can then be isolated and treated. Current tests are either too expensive to be useful where they are most needed, or not sensitive enough to provide accurate diagnosis. PCR testing is highly sensitive but expensive and complicated, requiring specialized skills and equipment. Testing with the ELISA gold strip is inexpensive, but sensitivity is low.
“Our new strip test is a simple, one-step test that is cheap and easy to use, and provides a visible signal, which means people don’t need training to use it. We think it will be especially helpful in rural areas,” said Prof. Yan, “We’re very excited about our new nanozyme test, as it is much more sensitive and you don’t need any specialist equipment to get a quick, accurate result.” Her colleagues at the Chinese Center for Disease Control and Prevention (CDC) will field-test it in West Africa for its EBOV diagnostic and screening potential. The researchers are also developing automatic equipment to reduce risk of test contamination from hand-contact.
The nanozyme test is the result of an interdisciplinary collaboration of scientists and clinicians. The researchers are collaborating to develop this robust technology further as it can be applied for detection of other biological molecules, making it useful to diagnose additional infectious diseases and to potentially detect cancer tumors. It is also being tested for its potential to help in decontamination for wastewater treatment.
“We had an idea and talked to many people about it, and the result is a test that will overcome a problem,” said Prof. Yan, “We have built strong collaborations that have finally made this method successful, and we’re looking forward to applying it to many other areas.”
The study, by Duan D et al., was published online ahead of print 11 May 2015, in the journal Biosensors and Bioelectronics.
Related Links:
Chinese Academy of Sciences
Elsevier
Latest Microbiology News
- Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
- Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
- Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
- Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
- Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
- New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
- Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
- Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
- Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
- FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
Channels
Clinical Chemistry
view channel
Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more
Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
Lipoprotein(a) is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease, yet routine screening remains uncommon despite guideline recommendations, leaving many high-risk... Read more
Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease
Alzheimer’s disease is a progressive neurodegenerative disorder marked by amyloid-beta and tau pathology and remains a leading cause of cognitive decline in older adults. Although lecanemab, an anti-amyloid... Read moreMolecular Diagnostics
view channel
Blood-Based DNA Analysis Method Detects Early-Stage Solid Cancers
Early detection of stage I solid cancers remains a significant unmet clinical need. Liquid biopsy approaches that can distinguish tumor-derived signals from background cell-free DNA are therefore drawing... Read more
Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
Predicting when Alzheimer’s disease will manifest remains a major clinical challenge, particularly before cognitive decline is evident. Blood biomarkers and genetic risk markers can flag elevated risk,... Read moreHematology
view channel
Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
Immune-mediated thrombosis following heparin therapy can be sudden and severe, creating urgent diagnostic challenges. In heparin-induced thrombocytopenia (HIT), antibodies against platelet factor 4 (PF4)... Read more
Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. In older adults, both high and low values have been linked to adverse outcomes, including cognitive... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read morePathology
view channel
AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
Predicting which patients with pancreatic cancer will recur after treatment and surgery remains challenging. Pathology evaluation typically measures residual tumor burden, but recent work found that tumor... Read more
Hybrid Computational Imaging Method Improves Digital Pathology Resolution
Digital pathology depends on high-resolution whole-slide imaging to capture diagnostically relevant cellular and tissue features, yet conventional methods often force trade-offs between speed, cost, and detail.... Read moreTechnology
view channel
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Unilabs Expands Digital Pathology Across European Network with Proscia Platform
As precision medicine expands, digital pathology platforms must connect teams, sites, diagnostic data, and artificial intelligence to accelerate routine diagnosis. Sharing expertise across laboratory networks... Read more
MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
MGI Tech Co., Ltd. (Shenzhen, China) introduced VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence staining and imaging system, at the 38th European Congress of Pathology (ECP 2026)... Read more







